Travere Therapeutics

Travere Therapeutics(TVTX)

SAN DIEGO, CA
Biotechnology

Focus: Small Molecules, Biologics

Travere Therapeutics is a life sciences company focused on Small Molecules, Biologics.

NephrologyRare DiseasesNeurologyMetabolic DiseasesCardiovascular
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
14

Products & Portfolio (1)

Pipeline & Clinical Trials

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
Homocystinuria Due to CBS Deficiency
N/A
Clinical Trials (1)
NCT02998710Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
N/A
Rare Group Problem Management Plus
Anxiety
N/A
Clinical Trials (1)
NCT06548022Rare Group Problem Management Plus
N/A
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropath
Focal Segmental Glomerulosclerosis
N/A
Clinical Trials (1)
NCT05200871Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
N/A
N/A
Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
N/A
Clinical Trials (1)
NCT02638220Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
N/A
RE-021, sparsentan
Healthy Subjects
Phase 1
Clinical Trials (1)
NCT05562362Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
Phase 1
Phase 1
Clinical Trials (1)
NCT07224776Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Phase 1
Pegtibatinase
Homocystinuria
Phase 1/2
Clinical Trials (1)
NCT03406611Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)
Phase 1/2
Clinical Trials (1)
NCT05003986Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2
Clinical Trials (1)
NCT01613118Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Phase 2
Clinical Trials (1)
NCT05630612ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Phase 2
Clinical Trials (1)
NCT05856760A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Phase 2
Clinical Trials (1)
NCT04663204A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
Phase 2
Pegtibatinase
Homocystinuria
Phase 3
Clinical Trials (1)
NCT06431893A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
Phase 3
Clinical Trials (1)
NCT03041116Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
Phase 3
Clinical Trials (1)
NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Phase 3
Pegtibatinase
Homocystinuria
Phase 3
Clinical Trials (1)
NCT06247085A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
Phase 3
Clinical Trials (1)
NCT03762850A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Phase 3
Sparsentan
Proteinuria
Phase 4
Clinical Trials (1)
NCT07219121Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Phase 4

Open Jobs (14)

Interview Prep Quick Facts
Portfolio: 1 approved product, 18 clinical trials
Top TAs: Nephrology, Cardiovascular, Immunology
SEC Filings: 2 available
Open Roles: 14 active jobs
Portfolio Health
Peak1 (100%)
1 total products
Therapeutic Area Focus
Nephrology
7 pipeline
Cardiovascular
1 marketed
Immunology
1 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$145M33%
R&D Spend
$245M(169%)8%
Net Income
-$111M
Cash
$59M

Hiring Trend

Stable
14
Open Roles
+4
Added
-3
Filled/Removed

Based on last 4 crawl cycles